The Jewish General Hospital
Welcome,         Profile    Billing    Logout  
 150 Trials 
227 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oza, Amit M
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
CAN-STAMP, NCT04159155: A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

Recruiting
2/3
267
Canada
External Beam Radiation, Niraparib, Zejula, Vaginal high-dose rate brachytherapy, Observation - no drugs
University Health Network, Toronto
Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
09/25
09/27
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
NCT01081951 / 2009-015970-36: Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Active, not recruiting
2
162
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, paclitaxel, Taxol, carboplatin, Drug: carboplatin
AstraZeneca
Ovarian Cancer
10/11
12/24
NCT03016338: Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Active, not recruiting
2
51
Canada
Niraparib, MK4827, TSR-042, Dostarlimab
University Health Network, Toronto, Tesaro, Inc.
Endometrial Cancer
01/21
12/25
NCI-2014-00620, NCT02101775: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
124
Canada, US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
02/22
02/25
NEO, NCT02489006 / 2016-002573-35: A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Active, not recruiting
2
71
Europe, Canada, RoW
Olaparib, Lynparza, Platinum-based Chemotherapy
University Health Network, Toronto, AbbVie, AstraZeneca
Ovarian Cancer, Fallopian Tube Cancer, Neoadjuvant Treatment, Debulking Surgical Procedures
12/25
12/25
PESCO, NCT03029403: Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active, not recruiting
2
47
Canada
Pembrolizumab, Keytruda, DPX-Survivac, Cyclophosphamide, Procytox
University Health Network, Toronto, Merck Sharp & Dohme LLC, ImmunoVaccine Technologies, Inc. (IMV Inc.)
Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
12/24
02/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT03480776: ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Active, not recruiting
2
117
Canada, RoW
Acetylsalicylic acid, ASA, Placebo
Canadian Cancer Trials Group, Apotex Inc.
Ovarian Cancer Prevention
06/25
12/25
OPAL, NCT03574779: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Hourglass Oct 2019 - Dec 2019 : Proof-of-concept data from OPAL trial in combination with dostarlimab and Avastin for 2L+ PROC ovarian cancer
Active, not recruiting
2
125
Europe, Canada, US, RoW
Niraparib, ZEJULA, TSR-042, Bevacizumab, Avastin, Carboplatin, Paclitaxel
Tesaro, Inc.
Ovarian Neoplasms
08/25
04/27
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
EPOCH, NCT05619913: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Recruiting
2
30
Europe, Canada, RoW
Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda
Australia New Zealand Gynaecological Oncology Group, Eisai Inc., Merck Sharp & Dohme LLC
Ovarian Carcinosarcoma, Uterine Carcinosarcoma
12/24
12/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
NCT04260802: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Recruiting
1/2
116
Canada
OC-001, Drug: OC-001 in Combination with Avelumab
Ocellaris Pharma, Inc.
Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer
03/26
09/26
NCT02632448: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Recruiting
1/2
229
Europe, Canada, US, RoW
LY2880070, Gemcitabine, Gemzar
Esperas Pharma Inc.
Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
09/25
09/25
CX-5461-04, NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Recruiting
1
52
Canada, US
CX-5461, Pidnarulex
Senhwa Biosciences, Inc.
Advanced Solid Tumor
12/24
06/25
Exactis-03, NCT05358639: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Active, not recruiting
1
36
Canada
Olaparib tablet, Lynparza, Navitoclax, ABT-263
Sunnybrook Health Sciences Centre, Exactis Innovation, Centre hospitalier de l'Université de Montréal (CHUM), Princess Margaret Hospital, Canada
High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
03/25
04/25
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
SGNALPV-001, NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors

Terminated
1
43
Europe, Canada, US
SGN-ALPV
Seagen Inc.
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
12/23
12/23
NCT02341118: Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.

Terminated
N/A
109
Canada
BRCA genetic data
University Health Network, Toronto
Ovarian Cancer
04/18
05/23
NCT06254781: Luspatercept in Metastatic AGCT of the Ovary

Completed
N/A
1
Canada
Luspatercept, Reblozyl
University Health Network, Toronto
Adult Granulosa Cell Tumor of the Ovary
08/22
08/22
NCT06328491: Erdafitinib in Metastatic Steroid-cell Ovarian Cancer

Completed
N/A
1
Canada
Erdafitinib, Balversa
University Health Network, Toronto
Ovarian Cancer, Steroid Cell Tumor, Malignant
08/22
08/22
NCT02334761: Biopsies in Oncology - Prospective Study of Impact on Patient's Quality of Life.

Completed
N/A
129
Canada
University Health Network, Toronto
Pathology
12/22
12/22
RESPECT, NCT04574765: A Research Platform to Screen Healthcare Workers- Coordinated Approach to Pandemic Trials of COVID-19

Active, not recruiting
N/A
100000
Canada
Nasopharyngeal swab, Questionnaire collection, Optional blood completion, Optional questionnaire completion
University Health Network, Toronto
Healthcare Worker, Covid19
12/24
12/24
MAMBO, NCT03260647: Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction in Gynecological Cancers

Recruiting
N/A
150
Canada
Management algorithm for Malignant Bowel Obstruction
University Health Network, Toronto
Gynecologic Cancer
12/24
12/24
VENUS, NCT03420118: Study of Biomarkers in Gynecological Cancers

Recruiting
N/A
500
Canada
Tumour tissue collection, Blood draws
University Health Network, Toronto
Gynecologic Cancer
12/24
12/25
UNIQUE, NCT06285500: Umbrella Study for Single Patient Treatments in Oncology

Recruiting
N/A
400
Canada
Patient-specific treatments
University Health Network, Toronto
Advanced Cancer, Rare Diseases
02/27
02/29
NCT03419689: Study Looking at Biomarkers in Ovarian Cancer

Recruiting
N/A
510
Canada
Tumour tissue collection, Blood sample collection, Ascites Collection, Fluid Collection
University Health Network, Toronto
Gynecologic Cancer
06/26
06/26
Siu, Lillian L
MET4-IO, NCT03686202: Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy

Active, not recruiting
2/3
65
Canada
MET-4
University Health Network, Toronto, NuBiyota
All Solid Tumors
12/24
12/25
INSPIRE, NCT02644369: Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors

Active, not recruiting
2
100
Canada
Pembrolizumab, Keytruda(TM), MK-3475
University Health Network, Toronto, Merck Sharp & Dohme LLC
Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma, Advanced Solid Tumors
12/24
12/24
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
MERIDIAN, NCT05414032: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

Recruiting
2
200
Canada
AZD2936
University Health Network, Toronto, AstraZeneca, NeoGenomics Laboratories
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
07/26
07/26
CAPTIV-8, NCT04273061: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Recruiting
2
200
Canada
Atezolizumab, TECENTRIQ
British Columbia Cancer Agency, Hoffmann-La Roche
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
10/27
10/27
KEYNOTE-A10, NCT03058289: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Checkmark Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Nov 2021 - Nov 2021: Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Completed
1/2
111
Canada, US
INT230-6, anti-PD-1 antibody, pembrolizumab, KEYTRUDA®, MK-3475, anti-CTLA-4 antibody, ipilimumab, Yervoy, BMS-734016
Intensity Therapeutics, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
02/23
02/23
START-001, NCT05592626: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Recruiting
1/2
365
Europe, Canada, US
STAR0602
Marengo Therapeutics, Inc.
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
10/26
10/26
NCT02007382: Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction

Recruiting
1
68
US, Canada
Trametinib, GSK1120212
University Health Network, Toronto, National Cancer Institute (NCI)
Solid Tumors, Hepatic Dysfunction
06/15
12/15
NCT03894618: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Completed
1
49
Europe, Canada, US
SL-279252
Shattuck Labs, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
05/23
05/23
NCT02070549: Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Active, not recruiting
1
46
Canada, US
Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
12/24
12/25
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
NCI-2021-13901, NCT05172245: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Recruiting
1
46
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasal Cavity Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Paranasal Sinus Squamous Cell Carcinoma, Locally Advanced Sinonasal Squamous Cell Carcinoma, Maxillary Sinus Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
06/26
06/26
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
PRE-MERIDIAN, NCT04599309: Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting
N/A
35
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
03/23
12/24
SPECIAL, NCT02724488: Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies

Active, not recruiting
N/A
14
NA
University Health Network, Toronto, Princess Margaret Hospital, Canada
Head and Neck Cancer, Melanoma
12/25
12/25
IRIS, NCT04243720 / 2011-004908-37: Immune Resistance Interrogation Study

Recruiting
N/A
100
Canada
University Health Network, Toronto
Cancer, Solid Tumor, Metastatic Cancer, Immune Resistance
02/25
02/25
COMPARISON, NCT03364621: Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Active, not recruiting
N/A
17
Canada
University Health Network, Toronto, Terry Fox Research Institute, British Columbia Cancer Agency
Colorectal Cancer, Colorectal Cancer Metastatic, Hepatic Metastases
06/25
06/25
LIBERATE, NCT03702309 / 2020-001203-16: Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Recruiting
N/A
2500
Canada
University Health Network, Toronto
Cancer, Breast Cancer, Lung Cancer, Colon Cancer, Ovarian Cancer, Melanoma, Lymphoma, Leukemia, Mutation, Lynch Syndrome, Cowden Syndrome, BRCA1 Mutation, BRCA2 Mutation, Uterine Cancer, Myeloma, Kidney Cancer, Head and Neck Cancer, Meningioma
07/25
07/25
NIP IT!, NCT05196087: Non-Invasive Artificial Intelligence-Based Platform MonIToring Program

Recruiting
N/A
500
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
06/26
06/26
OCTANE, NCT02906943: Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

Recruiting
N/A
10000
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer
08/26
08/26
MOHCCN-O, NCT05403177: Marathon of Hope Cancer Centres Network Study for Ontario

Recruiting
N/A
500
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada, Ontario Institute for Cancer Research, Terry Fox Research Institute
Breast Cancer, Colorectal Cancer, Pancreas Cancer, Kidney Cancer, Prostate Cancer, Ovary Cancer, Head and Neck Cancer, Leukemia, Lymphoma, Lung Cancer, Melanoma, Solid Tumor
10/26
10/26
Chi, Kim N
EvoPAR-PR01, NCT06120491: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Recruiting
3
1800
Europe, Canada, Japan, US, RoW
Saruparib, AZD5305, Placebo, Abiraterone Acetate, Zytiga, Darolutamide, Nubequa, Enzalutamide, Xtandi
AstraZeneca
Metastatic Castration-Sensitive Prostate Cancer
01/28
04/31
NCT02905318: Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
19
Canada
Palbociclib
Canadian Cancer Trials Group, Pfizer
Prostate Cancer
04/22
12/24
NCT03385655: Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting
2
200
Canada
Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab, Carboplatin
Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network, BC Cancer Foundation
Prostate Cancer
12/24
12/25
CCTG PR21, NCT04663997: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Active, not recruiting
2
200
Canada
177Lu-PSMA-617, Docetaxel
Canadian Cancer Trials Group, Prostate Cancer Canada, Novartis Pharmaceuticals
Prostate Cancer
06/25
12/25
PROTRACT, NCT04015622: PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

Recruiting
2
100
Canada
Enzalutamide, Xtandi, Docetaxel, Taxotere
British Columbia Cancer Agency
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
04/25
12/25
NCT02007382: Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction

Recruiting
1
68
US, Canada
Trametinib, GSK1120212
University Health Network, Toronto, National Cancer Institute (NCI)
Solid Tumors, Hepatic Dysfunction
06/15
12/15
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Kahn, Susan R
TILE, NCT04794569: Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Terminated
4
9
Canada
tinzaparin, Rivaroxaban
Sunnybrook Health Sciences Centre, LEO Pharma, Sunnybrook Research Institute
Deep Vein Thrombosis, Post Thrombotic Syndrome
01/24
01/24
COBRRA, NCT03266783: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Recruiting
4
2760
Europe, Canada, RoW
Apixaban, Eliquis, Rivaroxaban, Xarelto
Ottawa Hospital Research Institute, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Institutes of Health Research (CIHR)
Venous Thromboembolism
12/24
12/24
MUFFIN-PTS, NCT03833024: The Trial

Active, not recruiting
3
88
Canada
Micronized Purified Flavonoid Fraction, Venixxa group, Placebo, Placebo group
Sir Mortimer B. Davis - Jewish General Hospital
Post-Thrombotic Syndrome
03/24
05/24
SAVER, NCT04319627 / 2021-001559-15: Statins for Venous Event Reduction in Patients With Venous Thromboembolism

Recruiting
3
2700
Europe, Canada
Rosuvastatin Calcium, Rosuvastatin, Placebo Oral Tablet, Placebo
Ottawa Hospital Research Institute, The Canadian Institutes of Health Research (CIHR)
Venous Thromboembolism, Blood Clot, Post Thrombotic Syndrome
01/26
01/27
Johnson, Nathalie
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark ASH 2013
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
NCT05180097: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
84
Canada, RoW
Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab
Canadian Cancer Trials Group, Merck Sharp & Dohme LLC, Seagen Inc., Australasian Leukaemia and Lymphoma Group
Hodgkin Lymphoma
06/25
06/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Cheung, Patrick C F
STABLE-MATES, NCT02468024: JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Recruiting
3
272
Europe, Canada, US, RoW
Lung Surgery, SR, Radiation therapy, SAbR
University of Texas Southwestern Medical Center
Non-Small Cell Lung Cancer
12/28
12/28
SPARTACUSII, NCT04890912: Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II

Recruiting
2
50
Canada
Conventional Fractionation, Hypofractionation
Sunnybrook Health Sciences Centre, Princess Margaret Hospital, Canada, Royal Victoria Hospital, Canada, Credit Valley Hospital, London Regional Cancer Program, Canada
Endometrial Cancer
06/22
06/23
CROP, NCT02563691: Stereotactic Radiotherapy for Oligometastatic Prostate Cancer

Active, not recruiting
1/2
90
Canada
stereotactic radiotherapy, SBRT, SABR
Sunnybrook Health Sciences Centre
Prostatic Neoplasms
12/21
12/22
NCT04619069: Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Active, not recruiting
1/2
30
Canada
SBRT, Hormone therapy
Sunnybrook Health Sciences Centre
Prostate Cancer
10/25
10/27
NCT03526510: Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer

Active, not recruiting
N/A
178
Canada
Conventionally Fractionated versus Hypofractionated Boost
Dr. Patrick Cheung
Prostate Cancer
11/21
12/24
FIRST STAR, NCT05597852: Using Rectal Hydrogel Spacer for Salvage SABR in Prostate Cancer

Recruiting
N/A
10
Canada
SpaceOAR
Sunnybrook Health Sciences Centre
Prostate Cancer
11/22
11/27
RCT-PHART2, NCT04239599: Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer

Active, not recruiting
N/A
178
NA
Hypofractionated IMRT Radiation treatment, Eligard 22.5 mg (28.2 mg leuprolide acetate per syringe) [3-Month] for 18-36 months
Sunnybrook Health Sciences Centre, Sanofi
Prostate Cancer
12/23
12/23
PLATON, NCT03784755: Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

Recruiting
N/A
410
Canada
Ablative Radiation Therapy, SBRT, Stereotactic External Beam Irradiation, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, Standard of care
Canadian Cancer Trials Group, Canadian Cancer Society (CCS)
Prostate Cancer Metastatic
12/26
07/27
Hotte, Sebastien
NCT02788773: Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Active, not recruiting
2
52
Canada
Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Prostate Cancer
11/21
12/24
NCT03385655: Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting
2
200
Canada
Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab, Carboplatin
Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network, BC Cancer Foundation
Prostate Cancer
12/24
12/25
NCT03990454: Safety Study of SLC-391 in Subjects With Solid Tumors

Completed
1
35
Canada
SLC-391
SignalChem Lifesciences Corporation
Solid Tumor
06/23
06/23
Assouline, Sarit
NCT05413915: Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Recruiting
3
164
Canada
Asciminib, ABL-001, Imatinib, Imatinib mesylate
Sarit Assouline, Novartis
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia in Remission
12/25
12/25
MyeloMATCH, NCT05564390: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH ( Screening Trial)

Recruiting
2
2000
Canada, US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Best Practice, standard of care, standard therapy, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Echocardiography, EC, Enasidenib, AG 221, AG-221, AG221, CC-90007 Free Base, Gilteritinib, ASP 2215, ASP-2215, ASP2215, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
05/29
05/29
CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
1
18
Canada
Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab
Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation
Lymphoma, B-Cell
12/25
07/26
SL03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML

Active, not recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
11/24
11/24
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
TFR-PRO, NCT04621851: Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation

Recruiting
N/A
3000
Europe, Canada
University of Milano Bicocca
Chronic Myeloid Leukemia
09/21
09/23
Mukherjee, Som
NCT03385655: Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting
2
200
Canada
Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab, Carboplatin
Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network, BC Cancer Foundation
Prostate Cancer
12/24
12/25
SCHOLAR-2, NCT04680442: Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Recruiting
2
130
Canada, RoW
Trastuzumab, Herceptin, Herzuma, Ogivri, Trazimera, Kanjinti, Pertuzumab, Perjeta, Trastuzumab emtansine, Kadcyla,
Population Health Research Institute
Breast Cancer, Heart Failure
01/25
06/25
IMPACT, NCT06323707: The Implementation-Effectiveness Trial

Recruiting
2
129
Canada
Exercise, Self-management e-module
McMaster University, Canadian Cancer Society (CCS), Hamilton Health Sciences Corporation, Niagara Health System
Cancer
03/27
03/27
PET MUSE, NCT02462239: Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Completed
N/A
292
Canada
Whole-body FDG PET-CT, PET-CT imaging
Ontario Clinical Oncology Group (OCOG), Cancer Care Ontario
Muscle-invasive Bladder Cancer
03/24
11/24
Tagalakis, Vicky
ATTACC-CAP, NCT05848713: AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Recruiting
3
4000
Canada, US, RoW
Heparin
University of Manitoba, Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI
Community-acquired Pneumonia
03/28
03/29
MVTEP2/SOME2, NCT04304651: Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism

Recruiting
N/A
1276
Europe, Canada
Limited cancer screening, Limited cancer screening + FDG PET/CT
University Hospital, Brest, Ministry of Health, France, Canadian Institutes of Health Research (CIHR), Ottawa Hospital Research Institute
Embolism and Thrombosis
09/26
09/30
Ong, Michael K
TRIPLE-SWITCH, NCT06592924: Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People With Metastatic Castration Sensitive Prostate Cancer and Less Than Optimal PSA Response

Not yet recruiting
3
830
NA
Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, Alliance for Clinical Trials in Oncology, SWOG Cancer Research Network
Prostate Cancer (Adenocarcinoma)
03/31
04/31
RADIANT, NCT04543110: Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Recruiting
2
16
Canada
Durvalumab, (MEDI4736), Immune Modulating Radiation, Neoadjuvant Immune Modulating Radiation
Ottawa Hospital Research Institute, Cross Cancer Institute, Hamilton Health Sciences Corporation, London Health Sciences Centre, Ontario Institute for Cancer Research, AstraZeneca, Ozmosis Research Inc.
Bladder Cancer
10/23
11/24
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Mucosal Melanoma of the Urinary System, Nasopharyngeal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/25
12/25
NCT03385655: Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting
2
200
Canada
Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab, Carboplatin
Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network, BC Cancer Foundation
Prostate Cancer
12/24
12/25
NCT05174611: Vitamin D to Improve Quadricep Muscle Strength

Recruiting
2
60
RoW
Vitamin D3, Placebo
Chinese University of Hong Kong
Anterior Cruciate Ligament Injuries, Quadriceps Muscle Atrophy, Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Tear
03/25
09/25
NCT06129084: A Study to Compare the Results of FGFR Testing by Either CtDNA Blood Testing or Standard Tumor Tissue Testing

Recruiting
N/A
260
Canada
FGFR Testing
Bernie Eigl, Vancouver Prostate Centre, Lady Davis Institute, Bladder Cancer Canada
Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma
03/25
05/25
NCT05693493: Can Proprioceptive Knee Brace Improve Functional Outcome Following TKA?

Recruiting
N/A
30
RoW
Proprioceptive knee brace
Chinese University of Hong Kong
Knee Osteoarthritis
06/24
09/24
REGENETEN, NCT04450342: ™ Bioinductive Implant System in Full-thickness Tears

Terminated
N/A
119
Europe, Canada, US, RoW
Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation, Arthroscopic rotator cuff repair, Arthroscopic rotator cuff repair for revision surgery
Smith & Nephew, Inc.
Rotator Cuff Injuries
10/23
10/23
 

Download Options